These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37226909)

  • 1. A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States.
    Gaeta Gazzola M; Carmichael ID; Christian NJ; Zheng X; Madden LM; Barry DT
    Subst Abus; 2023; 44(1):62-72. PubMed ID: 37226909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder.
    Cook RR; Jaworski EN; Hoffman KA; Waddell EN; Myers R; Korthuis PT; Vergara-Rodriguez P
    Subst Abus; 2023 Oct; 44(4):301-312. PubMed ID: 37842910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness.
    Han BH; Doran KM; Krawczyk N
    J Subst Abuse Treat; 2022 Jan; 132():108504. PubMed ID: 34102461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.
    Krawczyk N; Williams AR; Saloner B; Cerdá M
    J Subst Abuse Treat; 2021 Jul; 126():108329. PubMed ID: 34116820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
    Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
    Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets.
    Hsu M; Jung OS; Kwan LT; Jegede O; Martin B; Malhotra A; Suzuki J
    J Subst Use Addict Treat; 2024 Feb; 157():209216. PubMed ID: 37981243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of death during outpatient treatment for opioid use disorder: A national study.
    Goldman JE; Samuels EA; Rich JD; Marshall BDL
    J Subst Abuse Treat; 2020 May; 112():76-85. PubMed ID: 32199549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
    Friesen EL; Kurdyak P
    Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbid Health Conditions and Treatment Utilization among Individuals with Opioid Use Disorder Experiencing Homelessness.
    Ali MM; Sutherland H; Rosenoff E
    Subst Use Misuse; 2021; 56(4):571-574. PubMed ID: 33637031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
    McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
    Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Medicaid expansion on inclusion of medications for opioid use disorder in homeless adults' treatment plans.
    Swartz N; Odayappan S; Chatterjee A; Cutler D
    J Subst Use Addict Treat; 2023 Sep; 152():209059. PubMed ID: 37207834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.
    Askari MS; Martins SS; Mauro PM
    J Subst Abuse Treat; 2020 Jul; 114():108028. PubMed ID: 32527510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis.
    Solomon KT; Bandara S; Reynolds IS; Krawczyk N; Saloner B; Stuart E; Connolly E
    J Subst Abuse Treat; 2022 Jan; 132():108424. PubMed ID: 34144299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
    Cook RR; Foot C; Arah OA; Humphreys K; Rudolph KE; Luo SX; Tsui JI; Levander XA; Korthuis PT
    Addict Sci Clin Pract; 2023 Feb; 18(1):11. PubMed ID: 36788634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings.
    Pham H; Ober A; Baldwin LM; Mooney LJ; Zhu Y; Fei Z; Hser YI
    J Addict Med; 2024 May-Jun 01; 18(3):331-334. PubMed ID: 38315721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.